Transversus abdominis plane (TAP) blocks have been shown to significantly reduce pain and narcotic consumption following several major abdominal surgeries; however, their widespread adoption in microsurgical breast reconstruction has been slow. This study investigates the current body of evidence on the use of TAP blocks in microsurgical breast reconstruction.
PURPOSE:
Transversus abdominis plane (TAP) blocks have been shown to significantly reduce pain and narcotic consumption following several major abdominal surgeries; however, their widespread adoption in microsurgical breast reconstruction has been slow. This study investigates the current body of evidence on the use of TAP blocks in microsurgical breast reconstruction.
METHODS:
A systematic review of patients undergoing autologous breast reconstruction with TAP blocks was performed. Information on patient demographics, pain scores, and postoperative narcotic consumption were noted. Metaanalysis of hospital length of stay (LoS) was performed using a random effects model.
RESULTS:
Ten studies published between 2011 and 2018 were included. All studies were either a randomized control trial/prospective case-control study (LoE II [5, 50%]) or a retrospective cohort study (LoE III [5, 50%] ). Across all studies, 174 patients (5 studies) received a single intraoperative TAP block injection, 185 patients (4 studies) received a TAP catheter for intermittent postoperative analgesia, and 325 patients served as controls for a total of 684 included patients. The majority of TAP block delivery techniques were ultrasound guided (7/10 studies). Liposomal bupivacaine (LB) was the most commonly used analgesic (4 studies, 139 patients) followed by conventional bupivacaine (3 studies, 105 patients). Studies reported on a mixed cohort of both unilateral and bilateral, and immediate and delayed reconstructions. Abdominally based flaps investigated included deep inferior epigastric perforator, MS-TRAM, TRAM, and superficial inferior epigastric artery flaps. Nine of the included studies analyzed postoperative narcotic consumption with the use of TAP blocks. Of those, all but one found a significant reduction in oral, intravenous, and/ or total morphine requirements in the experimental TAP group when either the daily average and/or total inpatient consumption was compared to the control. Only 1 study performed a formal analysis of cost with the use of a LB TAP block and found no statistically significant increase in hospital expenses in the TAP block group. Hospital LoS was significantly shorter for patients undergoing single intraoperative TAP block injection with any analgesic as compared to standard narcotic-based protocols (mean difference, −0.95 days; 95% confidence interval, −1.72 to −0.17 days; P = 0.02). Looking at TAP blocks specifically with LB, there was a mean decrease of 0.83 days as compared to the control which was not statistically significant (95% confidence interval, −1.90 to 0.25 days; P = 0.13). No study reported adverse outcomes related to the TAP injections themselves. One prospective cohort study specifically looked at chronic postsurgical pain outcomes following the use of standard 0.25% bupivacaine delivered via TAP catheters and found no significant reduction in the incidence of chronic postsurgical pain at 6 and 12 months.
CONCLUSIONS:
Several high-quality studies have demonstrated that TAP blocks in microsurgical breast reconstruction significantly reduce narcotic consumption and hospital LoS. However, there remains considerable variability with regard to delivery technique, analgesic type, and dose. Although the current data support the use of TAP blocks in autologous breast reconstruction, additional studies with more standardized protocols should be performed to determine the most optimal practice.
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INTRODUCTION: Anatomical exclusion criteria for nipple-sparing mastectomy was defined as "not excessively large or ptotic breasts." However, morphologic criteria such as ptosis and sternal notch to nipple have not been shown to predict ischemic outcome. In this presentation, we introduce a novel midclavicular-to-inframammary (MCI) fold measurement for nipple-sparing mastectomy (NSM) performed through an inframammary approach and demonstrate it to be predictive of mastectomy weight and ischemic outcomes.
METHODS:
Retrospective review was performed on all NSM through an inframammary approach. Exclusion criteria include other mastectomy incisions, staged mastectomy, previous breast operation, and autologous reconstruction. Preoperative anatomical measurements for each breast, clinical course, and specimen weight were obtained.
RESULTS:
One hundred forty breasts in 79 patients were reviewed. Mastectomy weight was strongly correlated with MCI fold measurement on linear regression (R 2 = 0.651; P < 0.001) but neither ptosis nor sternal notch-to-nipple distance were. Twenty-five breasts (17.8%) had ischemic complications: 16 (11.4%) were nonoperative and 9 (6.4%) were operative. The average mastectomy specimen weight in patients with major ischemic complications was 498 g, significantly higher than mastectomy specimens without major complications (315 g; P = 0.001). Those with mastectomy weights ≥500 g were 9 times more likely to have operative ischemic complications than those with mastectomy weights <500 g (P = 0.0048). The average MCI fold measurement among breasts with major ischemic complications was 30.2 cm, significantly different from breasts without major ischemic complications (27.9 cm; P = 0.032). Those with MCI fold ≥30 cm had a 3.8 times increased incidence of any ischemic complication (P = 0.00547) and 9.2 times increase incidence of operative ischemic complications (P = 0.00376) compared with those <30 cm. The majority of patients with and without major ischemic complications had grade I ptosis (P > 0.05).
CONCLUSION:
Breasts undergoing NSM with inframammary approach with MCI fold measurement ≥30 cm are at high risk for having ischemic complications. Previous anatomical measurements, such as sternal notchto-nipple and ptosis, were not correlated with ischemic complications. Although our absolute contraindication to NSM remains MCI fold >34 cm, consideration for a staged approach or lateral incision is warranted in those ≥30 cm. L. Fan, MD; Peter Wirth, BA; Cara K.  Black, BA; Rachel C. Camden, MS;  Joseph Myers, MD; David H. Song, MD, 
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PURPOSE: Enhanced recovery after surgery (ERAS) is increasingly being used in breast reconstruction. It is a multidisciplinary approach to surgical patient care that aims to decrease preoperative stress and postoperative pain, increase quality of care, and expedite patient recovery. The benefits of ERAS for patients are manifold; however, it still remains to be determined which components of the ERAS pathway are most responsible for improvement in outcomes in the setting of microvascular free tissue transfer (FTT) breast reconstruction.
METHODS:
A retrospective chart review was performed for 42 FTT breast reconstruction patients at a single institution. Electronic medical records were used to assess demographics; pre-, intra-, and postoperative medications; and subjective pain scores. Outcomes of interest included average milligram morphine equivalents used per day, average self-reported pain, and number of antiemetic doses given during hospital stay. Linear regression was used to determine which ERAS medications correlated to these outcomes. We examined preoperative acetaminophen, gabapentin, and celecoxib; intraoperative lidocaine, ketorolac, and liposomal bupivacaine; and postoperative ketorolac, gabapentin, and acetaminophen.
RESULTS:
Postoperative gabapentin, a cortical neuronal calcium channel modulator, showed significant correlation with study variables. All else equal, gabapentin use was associated with a 59.8 mg decrease in average postoperative milligram morphine equivalents used per day (P = 0.001; −93.36 to −26.30); a 2.1-point decrease in average pain (P = 0.031; −4.01 to −0.21); and a 2.5 dose decrease in the number of antiemetic doses (P = 0.045; −4.88 to −0.056). Gabapentin decreased the odds of a patient receiving over 50 mg of oral morphine equivalent per day by 8.3 times (P = 0.0321; 1.255-54.707) and reduced the chances of average pain above 5 by 16 times (P = 0.0079; 2.186-117.094). It was also associated with 8.5 times decreased odds of a patient requiring over 5 antiemetic doses (P = 0.0910; 0.926-78.0261).
CONCLUSIONS:
In this single-center retrospective study, postoperative gabapentin use had the largest effect of all ERAS pathway analgesics on postoperative opioid use, pain, and antiemetic use. Gabapentin should therefore be especially considered for all FTT breast reconstruction patients. The effects of the other ERAS pathway analgesic medications may require larger sample sizes to evaluate. Further studies are required to further understand the effects of each component of the ERAS pathway on breast reconstruction patient outcomes.
